RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS-C
RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS-C
复制标题
DOI：
10.1016/0140-6736(91)91707-2
复制
发表时间：
1991-05-04
期刊：
影响因子：
168.9
通讯作者：
WEILAND, O
中科院分区：
文献类型：
--
作者：
REICHARD, O;ANDERSSON, J;WEILAND, O
我们在一项包含 10 名患者的试点研究中评估了口服利巴韦林作为慢性丙型肝炎感染的治疗方法。 患者（7 名男性，3 名女性；平均年龄 40 岁，范围 23-54 岁）均患有经活检证实的慢性非甲型、非乙型肝炎，并且丙型肝炎病毒抗体多次呈阳性。 治疗方法是每天口服利巴韦林 1000-1200 mg，分两次服用，持续 12 周。 所有患者入组时的中位血清丙氨酸氨基转移酶浓度为 3.15-mu-kat/I（范围 1.22-7.79），治疗 12 周后显着下降（p < 0.005）至 1.25-mu-kat/I（0.78-2.04）。 治疗结束后6周内，中位血清丙氨酸氨基转移酶浓度与治疗前没有显着差异。 副作用轻微且在停止治疗后完全可逆。 我们的结论是，利巴韦林是第一种对慢性丙型肝炎提供潜在有效口服治疗的药物。它应该在对照试验中进一步评估，可能与干扰素α联合使用。
We evaluated oral ribavirin as therapy for chronic hepatitis C infection in a pilot study including 10 patients. Patients (7 men, 3 women; mean age 40 years, range 23-54) all had biopsy-proven chronic non-A, non-B hepatitis and were repeatedly positive for antibodies to hepatitis C virus. Treatment was with oral ribavirin 1000-1200 mg per day in two divided doses for 12 weeks. The median serum alanine aminotransferase concentration for all patients at enrolment was 3.15-mu-kat/I (range 1.22-7.79) and decreased significantly (p < 0.005) to 1.25-mu-kat/I (0.78-2.04) after 12 weeks of treatment. Within 6 weeks of the end of treatment the median serum alanine aminotransferase concentration was not significantly different from that before treatment. Side-effects were mild and fully reversible after cessation of therapy. We conclude that ribavirin is the first drug to offer a potentially effective oral treatment for chronic hepatitis C. It should be further evaluated in controlled trials, possibly in combination with interferon alpha.